대한뉴팜

Entry into Next-Generation Bio Business through Domestic Supply of ‘Protein A’ “Core material for biopharmaceutical manufacturing, diversification of domestic supply routes opened” - Daehan New Pharm Co., Ltd. advances into the next-generation bio business with domestic supply of ‘Protein A’- Contributing to enhancing the international competitiveness of domestic pharmaceutical companies’ biopharmaceutical development by reducing costs- Breaking the exclusive supply structure and diversifying domestic supply of ‘Protein A’ through partnerships with Korea, US, China, and Japan Daehan New Pharm Co., Ltd. (CEO Bae Kun-Woo), a mid-sized KOSDAQ-listed pharmaceutical company, announced strategic partnerships with companies in Korea, the US, China, and Japan to diversify the domestic supply of ‘Protein A,’ an essential core material for biopharmaceutical production. With the expiration of patents on biopharmaceuticals, domestic companies accelerating biosimilar production can now escape the existing exclusive supply system and strengthen their international competitiveness in the biopharmaceutical field by reducing costs and improving research efficiency through diversified supply chains. Until now, domestic supply of ‘Protein A’ had been monopolized by GE (General Electric). In the strategic partnership, Daehan New Pharm has signed supply agreements with GenScript (US) and Pharmawin Japan, where GenScript handles product manufacturing and technical support, and Pharmawin oversees Asian sales marketing and technical support services. Itochu Shanghai (China) acts as coordinator for entry into the Chinese market, sharing advanced market experience and systems. The ‘Protein A’ supplied by Daehan New Pharm plays a crucial role in determining efficiency, time, cost, and purity in biopharmaceutical manufacturing. Korean companies, research institutes, and universities use ‘Protein A’ extensively in purification processes, with annual usage expected to exceed 5,000 liters, roughly worth 60 billion KRW. Major domestic biopharmaceutical companies include Celltrion, Samsung Biologics, LG Life Sciences, Hanwha Chemical, AProgen, HanAll BioPharma, Hanmi Pharmaceutical, and Green Cross, all anticipated to replace ‘Protein A’ every six months. Daehan New Pharm plans to expand its product portfolio through continuous technological partnerships and supply essential products for biopharmaceutical production in Korea, with future technology transfer expected to support market growth. CEO Bae Kun-Woo said, “The agreement includes mutual cooperation among four countries to continuously enhance Daehan New Pharm’s involvement in bio products and services and provide total solutions for biopharmaceutical processes. Daehan New Pharm holds the Korean market rights for ‘Protein A’ and will serve as a joint partner in expanding into the Asian market.” GenScript co-founder Dr. Luquan Wang and Pharmawin chairman Mr. Okamoto, participants in the signing ceremony, stated, “Discussions with Daehan New Pharm began early, and the agreement process has proceeded smoothly based on trust and cooperation. All four participating companies recognize their mutual importance and are determined to collaboratively pioneer the biopharmaceutical market.” Founded in 1984, Daehan New Pharm is a research and development-focused mid-sized pharmaceutical company that develops and produces a diverse range of products from specialty pharmaceuticals to obesity solutions, veterinary medicines, and genetic development. Since its KOSDAQ registration in 2002, it has moved toward specialized affiliated industries and entered the bio business to become a global pharmaceutical hidden champion aiming to create a comprehensive health and welfare company (Pharmatopia) for a healthy and happy life. ■ Reference: Bio Business Market OutlookThe global pharmaceutical market is approximately $769.7 billion, with biopharmaceuticals accounting for about $104.6 billion, approximately 13.6% of the total market. Biopharmaceuticals are rapidly growing at an average annual rate of about 17.3%, expected to exceed $160 billion in 2013 and account for over 30% of the total pharmaceutical market. Korea’s biopharmaceutical growth is also highly regarded abroad. The respected US RAND Institute projected that Korea’s biopharmaceutical technology would reach 95% of the US level by 2020 and predicted growth to 15 trillion KRW within seven years. Biopharmaceuticals are categorized as bio originals, biosimilars, and biobetters. Biosimilars are generic protein antibody drugs with verified safety and efficacy, requiring significantly lower R&D costs and shorter development times than new drug development. Since 2012, numerous blockbuster protein drug patents have expired, with 21 blockbuster protein drugs expiring over three years, generating about $73.9 billion in revenue. Biobetters improve upon original biopharmaceuticals by enhancing efficacy and reducing side effects. They are considered second-generation biopharmaceuticals following biosimilars. Biobetter development is ongoing in Korea, Japan, China, the US, and Europe, with the market expected to grow to approximately $400 billion by 2020.

The new veterinary product Deowigara has been newly launched to prevent heat stress in livestock during the summer season. Deowigara is a combined formulation of betaine and vitamin C that effectively regulates osmotic pressure to alleviate dehydration symptoms caused by heat stress and enhances productivity even during heatwaves. It also promotes lipid metabolism in the liver to relieve fatty liver and boosts immune function to improve overall productivity. Key Features: - Alleviates dehydration symptoms through osmotic pressure regulation- Reduces heat and coccidial stress- Mitigates and minimizes summer mortality- Enhances productivity in broilers and laying hens- Reduces feed formulation costs by replacing choline and methionine- Improves meat quality and relieves fatty liver in laying hens

Lipi-C Injection Enters the Chinese Market Despite challenges such as drug price reductions and FTA agreements, the pharmaceutical industry is seeking breakthroughs through overseas market expansion. On May 21, Daehan New Pharm Co., Ltd., a KOSDAQ-listed company, signed a three-year supply agreement with a Chinese pharmaceutical company (Guangdong Longkang) for its liver disease injection Phosphatidylcholine (brand name: Lipi-C Injection). After approximately 18 months of clinical trials, the product is expected to be released to the Chinese market, with sales projected to begin in 2014. The estimated revenue over the contract period is around KRW 30 billion (based on current transaction prices). Phosphatidylcholine, a liver disease treatment injection, is a unique product originally monopolized by Germany’s Lipoid GmbH, which supplies the raw material under an exclusive agreement with global pharmaceutical giant Sanofi Aventis, dominating the global market. In South Korea, only two companies, including Daehan New Pharm, hold approval for sales under the Ministry of Food and Drug Safety’s PMS (Post-Marketing Surveillance) program. Meanwhile, Sanofi Aventis maintains exclusive rights in China, generating approximately KRW 100 billion in annual sales for liver and fatty liver treatments. Daehan New Pharm has built its operations around specialization, focus, and globalization as its core strategy, aiming to become a healthcare pioneer that creates a richer world and happier lives through specialized products and customized solution-based marketing. The company operates its own wellness programs centered on vitamin and obesity treatment products, has achieved visible business results through innovative and differentiated strategies, and has already registered over 200 products in 40 countries. The recent contract for Chinese market entry is the outcome of this specialized portfolio, international business experience, strategic networking, and determination to overcome current challenges — a synergy expected to become a major growth engine for the company. Using the Lipi-C Injection’s entry into China as a foothold, Daehan New Pharm plans to expand its exports further within China and into Southeast Asian markets. The company’s strategic decision is expected to serve as a successful model for overcoming market difficulties in the pharmaceutical industry.

Daehan New Pharm Co., Ltd., Despite Decreased Sales and Profit, Strengthens Internal Stability Daehan New Pharm Co., Ltd. reported a first-quarter sales revenue of 10,777 million KRW, a 15.9% decrease compared to the same period last year, and an operating profit of 1,075 million KRW (operating profit margin of 10.0%), down 28.1%. The main reason for the reduced performance compared to last year’s quarter was the absence of special demand for disinfectants worth 2,153 million KRW due to foot-and-mouth disease starting at the end of 2010, which had boosted results in the first quarter of 2011. Excluding this special demand factor, sales and operating profit remained at similar levels. Since the second half of 2011, Daehan New Pharm has been promoting the "Start-up Daehan New Pharm Project," focusing on strengthening business competitiveness and profitability and restructuring products and distribution channels, improving the quality aspect of sales. In preparation for the drug price reduction and FTA enforcement starting from April 2012, Daehan New Pharm is strengthening its focus and specialization on core competencies and areas where multinational corporations or large pharmaceutical companies do not participate, such as obesity solutions. The company plans to continuously enhance its unique product structure and increase customer assets through direct transactions and distribution efficiency strategies. Through this business portfolio structure, the company aims to absorb the impact of drug price reductions while promoting differentiated strategies to become a small but strong enterprise.

A clinical trial conducted by the Institute of Veterinary Medicine at Gyeongsang National University on broiler farms in the Gyeongnam region, where coccidiosis outbreaks are common, found that administration of “Coccimyeol-S” significantly reduced mortality rates compared to the control group. The study also observed reductions in fecal diarrhea scores and intestinal lesion severity upon necropsy. Coccidiosis affects all poultry species but occurs most severely in chickens and turkeys, causing major economic losses in the poultry industry. The protozoan parasites inhabit the intestinal tract, leading to diarrhea and enteritis, and in broiler farms, resulting in watery, loose, or bloody feces, reduced weight gain, and delayed shipping dates. Through this clinical study, Daehan New Pharm confirmed that the group treated with “Coccimyeol-S” exhibited relatively higher weight gain compared to the untreated group (using 22-day-old broilers infected with Eimeria spp., tested by the Institute of Veterinary Medicine, Gyeongsang National University). “Coccimyeol-S” offers a shorter treatment period of just two days and an economical treatment cost of approximately 4–8 KRW per bird, compared to existing coccidiosis treatments. The withdrawal period is also short at only five days, allowing safe use even in cases of short shipping cycles. Moreover, the product shows minimal drug resistance and does not cause the side effects associated with traditional coccidiosis treatments, such as decreased water intake or weight gain. Daehan New Pharm has also newly launched “Lactoplanta,” an antibiotic alternative derived from fermented fish sauce. [Published in Poultry Research, March 2012.]

Lactoplanta (Lactic Acid Bacteria Derived from Fermented Fish Sauce) Launched

Health Digest Lecithin Therapy

Daehan New Pharm Co., Ltd.’s sales for the January to September period reached 34.1 billion KRW, maintaining a similar level to the previous year. Operating profit increased by 9.8% year-on-year to 4.3 billion KRW (operating profit margin 12.6%) due to results from restructuring and operational efficiency improvements. However, net income decreased by 1.3 billion KRW to 560 million KRW (net profit margin 1.6%), mainly due to litigation costs of 1.94 billion KRW incurred in early July, which were accounted for in the first half of the year. The company is currently appealing and the lawsuit is ongoing. Daehan New Pharm is proactively responding to the challenging business environment in the pharmaceutical industry, including drug price reductions, through management innovation initiatives under the mindset of "START-UP Daehan New Pharm Project." Along with strategic innovation to become the top specialist company in the Med Health (Welling) field, Daehan New Pharm is accelerating efforts to secure core competencies and modernize systems by restructuring product portfolios, strengthening distribution competitiveness, establishing a cash flow and profit-centered operating system, and fostering key talent with performance-based human resource management. The company expects that the first phase of innovation activities this year will be a strategic turning point yielding breakthrough results, and it is committed to continuously driving innovation to make this crisis a launching pad for its second leap forward.

Final Results of the Reassessment of Five Existing Drug Categories1. We hereby inform you of the final results and the effective dates of the revised drug prices for the five therapeutic categories that have been undergoing reassessment since the second half of last year. Please refer to the details below for your business operations. 2. Please note that the effective date of implementation differs by product. << Details >> (1) Price Changes Product Name Current Price 2011.7.1 2012.7.1 Tiparon Tab. (Tiropramide HCl) 195 156 Metazin Tab. 122 113 109 Mucoran Tab. (Rebamipide) 151 150 Asitoba Cap. 300 mg 195 181 173 Levoran Tab. (Levosulpiride) 194 180 177 Silotal Tab. (Cilostazol) 419 390 365 (2) Drug Price DeletionsEffective period: from July 1, 2011 to August 31, 2011 (insurance reimbursement applies during this period) Product Name Current Price Diphedin Inj. 2 mL 670 Mezotopy Inj. (Nicotinic Acid Ethofylline) 2,404 Ribendol Tab. (Alibendol) 104 Diazhe Tab. (Dimecrotinic Acid Magnesium) 97 End.